INTRODUCTION

Top Abstract Introduction Materials and methods Results Discussion References

Recent evidence indicates that in vertebrates, exons rather than introns may be the primary units of recognition during pre-mRNA splicing. Multiple splicing factors can bind cooperatively to splice sites flanking the exon and communicate across the exon (17, 19, 23, 35, 41, 51; reviewed in references 2, 3, 12, 34, and 50). Work in a number of laboratories has suggested that a strong downstream 5' splice site can facilitate splicing of an upstream intron by strengthening its 3' splice site via a network of protein interactions across the intervening exon (17, 19; reviewed in references 2 and 3).

Many exons are known to also contain auxiliary splicing elements known as exonic splicing enhancers (ESEs) (9, 10, 14, 15, 18, 22, 24, 25, 36, 38, 40, 42, 46, 49, 51-54). While most ESEs have been found in exons that are associated with alternative splicing events, they can also be found in constitutive exons. ESEs are associated with introns containing weak flanking splice sites and have been shown to function by strengthening interactions at upstream 3' splice sites (4, 24, 38, 40, 44-46, 51-53). The majority of ESEs that have been identified are purine-rich repeats of the canonical sequence GARGARGAR; however, non-purine-rich enhancers have also been identified (9, 11, 43, 44, 49, 51). Activation of purine-rich ESEs requires the binding of essential splicing factors called SR proteins (24, 33, 39; reviewed in references 12 and 26), and protein-protein interactions between SR proteins and other splicing factors are thought to contribute to the cooperative assembly of early splicing complexes (2, 12, 26, 34).

Recently, a new class of non-purine-rich enhancers with CA-rich motifs (called ACEs) was identified by in vivo selection experiments, and individual selected ACEs were found to enhance splicing both in vivo and in vitro (9). For example, the well-characterized Drosophila doublesex (dsx) splicing enhancer (dsxRE) contains a CA-rich motif (25, 44) that enhances the splicing of a vertebrate exon in vertebrate cells (9), and an ACE within cTNT exon 16 has recently been shown to promote the binding of U2AF⁶⁵ to the upstream 3' splice site of a heterologous transcript in vitro (51).

The parvovirus minute virus of mice (MVM) is organized into two overlapping transcription units, which produce three major transcript classes, R1, R2, and R3 (1, 6, 31) (Fig. 1). mRNAs R1 and R2 are generated from a promoter (P4) at map unit 4 (7, 31) and encode the viral nonstructural proteins NS1 and NS2, respectively. Both NS1 and NS2 play essential roles in viral replication and cytotoxicity (8), and so maintenance of their relative steady-state levels is critical to the MVM life cycle. P4-generated pre-mRNAs undergo alternative splicing, which determines the relative steady state ratios of mRNAs R1 and R2, thereby influencing the relative ratios of NS1 and NS2, respectively (5, 21, 28). There is approximately twice as much R2 as R1 present throughout infection of a wide variety of cell types (8, 55, 57), and all MVM mRNAs are very stable (37). The constitutive, alternative splicing of MVM pre-mRNAs must be accomplished solely by the interactions between cellular factors and viral cis-acting signals, because no viral proteins participate in this process (32).

There are two types of introns in MVM P4-generated transcripts. An overlapping downstream small intron, located between nucleotides (nt) 2280 and 2399, is common to both P4-generated transcripts (R1 and R2) and P38-generated transcripts (R3). This small intron undergoes an unusual pattern of overlapping alternative splicing by using two donors (D1 and D2) and two acceptors (A1 and A2) within a region of 120 nt (28). The determinants governing excision of the small intron are complex, and the intron appears to be excised by a hybrid of intron and exon definition mechanisms (16).

An upstream large intron, located between nt 514 and 1989, is also excised from a subset of P4-generated pre-mRNAs to generate R2 mRNA. This upstream intron utilizes a nonconsensus donor and has a weak polypyrimidine tract, as defined by the presence of several interrupting purines, at its 3' splice site. Excision of this intron from P4-generated pre-mRNA and the generation of the R2 mRNA require inclusion of the intervening NS2-specific exon as an internal exon.

The NS2-specific exon is an unusual internal exon in several ways. First, it occupies an unusual position flanked by a large intron upstream and a small intron downstream, in contrast to most vertebrate internal exons, which are flanked by large introns on both sides. Second, it is 290 nt, i.e., within the upper 5% of vertebrate exon size limits (2). Finally, the alternatively spliced NS2-specific exon is translated in two open reading frames (ORFs): when included in singly spliced R1, this exon is translated in ORF3 to encode NS1; when included in doubly spliced R2, the exon is translated in ORF2 to encode NS2.

We have previously shown that efficient excision of the upstream intron from P4-generated pre-mRNA depends upon the initial presence of downstream small intron sequences, including at least one downstream 5' splice site and one downstream 3' splice site, within the pre-mRNA (55, 57); prior splicing of the small intron, however, is not necessary. In the absence of both the downstream intron 5' splice sites (which constitute the 3' terminus of the NS2-specific exon), a new spliced product (here called the exon-skipped product [ES]) not seen during viral infection is produced, in which the NS2-specific exon is skipped and the upstream intron 5' splice site at nt 514 is joined to a downstream intron 3' splice site (55), predominantly A1 at nt 2377. Improvement of the polypyrimidine tract of the upstream intron 3' splice site (which constitutes the 5' terminus of the NS2-specific exon) not only can render its efficient excision independent of downstream intron sequences but also can suppress exon skipping caused by deletion of both the small intron donors (55). Inclusion of the NS2-specific exon also requires sequences within the exon itself; replacement of the entire exon by a heterologous exon sequence also results in uniform exon skipping (56). Finally, multiple determinants that govern excision of the small intron, including its small size and a G-rich intronic enhancer sequence, also participate in inclusion of the upstream NS2-specific exon (16).

In this study, we have performed an extensive mutational analysis of NS2-specific exon sequences, both at the termini and within the exon. We have identified a novel bipartite exonic enhancer, consisting of an unusual combination of CA-rich and purine-rich enhancer elements located at the 5' and 3' ends of the exon, respectively, that have at least partially redundant functions and function to mediate the proper levels of inclusion of the NS2-specific exon in both singly spliced (R1) and doubly spliced (R2) mRNA.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and methods Results Discussion References

Mutant construction. Construction of pD1/2, p4TD1/2, p5A, p1989, pEx(), and pEx() has been described previously (55, 56). The mutants pEx() and pEx() were generated by substituting two copies of NS2-specific exonic sequences from nt 2005 to 2270 in either the forward or reverse orientation, respectively, between the SmaI (nt 2005) and SmaI (nt 2270) sites of pEx() by standard recombinant DNA techniques. [RNA generated by the parent construct, pEx(), which contains two SmaI sites engineered at nt 2005 and 2270, was spliced identically to that of wild type (13, 56).] All the final mutant clones were sequenced to confirm that only the desired mutations were introduced.

Transfection and RNA isolation. Murine A92L cells, the normal tissue culture host for MVM(p), were grown as previously described (31) and transfected with wild-type and mutant MVM plasmids by using either DEAE-dextran (30) or Lipofectamine-Plus reagent (as described in the Lipofectamine-Plus reagent kit [Gibco BRL]). RNA was typically isolated 48 h posttransfection, after lysis in guanidinium thiocyanate, by centrifugation through CsCl exactly as previously described (37).

RNA analysis. (i) RNase protection assays. RNase protection assays were performed as previously described (37), with an [-³²P]UTP-labeled, SP6-generated antisense MVM RNA probe from either MVM nt 385 to 652 (probe A) or nt 1854 to 2378 (probe B) (Fig. 1). Probe A identifies all P4 products and distinguishes between R1 and the RNAs that use the nt 514 donor (R2+ES). Probe B extends from before the 3' splice site of the large intron to within the small intron common to all MVM RNAs and distinguishes between P4 (R1 and R2) and P38 (R3) species using the large intron 3' splice site and either of the alternative small-intron donors (designated M for the major splice donor [D1] at nt 2280 and m for the minor splice donor [D2] at nt 2317 [37]). Unspliced P4 and unspliced P38 products are designated R1un and R3un, respectively. R1, R2, and R3 RNAs using D1 at nt 2280 (Fig. 1) are designated R1M, R2M, and R3M, respectively. R1, R2, and R3 RNAs using D2 at nt 2317 (Fig. 1) are designated R1m, R2m, and R3m, respectively. Thus, probe B can distinguish between unspliced, minor, and major forms of both R1 and R2; however, it cannot detect the ES. For analysis of RNA produced after transfection with mutants containing mutations within this region covered by probe B (pD1/2, p1TD1/2, p2TD1/2, and p4TD1/2), antisense RNase protection probes homologous to the mutants being analyzed were used. RNase protection products were analyzed on a Betagen -scanning phosphorimage analyzer, and molar ratios of MVM RNA were determined by standardization to the number of uridines in each protected fragment.

(ii) Quantitative RT-PCRs. First-strand cDNA synthesis used 5 µg of total RNA isolated after transfection and oligonucleotide dT priming by standard techniques (20). PCR detection of R2 and ES was performed with primers a and b (Fig. 1) as described previously (56) with minor modifications (6a). The forward primer (designated a in Fig. 1) was 5'-end labeled with [-³²P]ATP (as described in reference 27) and added to a 15-cycle PCR mixture (94°C for 1 min, 55°C for 1 min, and 72°C for 1 min, followed by a single extension at 72°C for 5 min). The ratio of the two products did not vary detectably over a wide range of dilutions and cycle numbers (15, 20, and 30 cycles). PCR products were run on 6% acrylamide-urea gels and analyzed on a Betagen -scanning phosphorimage analyzer, to calculate molar ratio of R2 to ES and obtain a direct value of percent R2/(R2+ES) (see Fig. 5A and D).

View larger version (13K): [in this window] [in a new window]   FIG. 1.   Genetic map of MVM. The three major transcript classes and protein-encoding ORFs are shown. The two promoters (P4 and P38) are indicated by arrowheads. The large intron, small intron, and NS2-specific exon are indicated. The nonconsensus donor (ncD) and the poor polypyrimidine tract [poor (Py)n] of the large intron are also shown. The bottom diagram shows nucleotide locations, the two probes (A [nt 385 to 650] and B [nt 1854 to 2378]) used for RNase protection assays, and the two primers [a (nt 326 to 345) and b (nt 2557 to 2538)] used for RT-PCR, as described fully in Materials and Methods.

	RESULTS

Top Abstract Introduction Materials and methods Results Discussion References

A bipartite enhancer within the NS2-specific exon is required for inclusion of this exon in mature spliced mRNA. To assess the relative accumulated levels of the P4-generated R2 and ES, we first established a quantitative RT-PCR assay, whose results were validated indirectly by quantitative RNase protection assays as described in Materials and Methods. We have previously shown that sequences within the NS2-specific exon are required for its inclusion in mature spliced mRNA (56). To further define the sequences required for efficient exon inclusion, RNA generated from mutants containing single deletions of regions within the exon was examined. Efficient inclusion of the NS2-specific exon was maintained following deletion of any of four regions alone (pSX, pXP, pPH, and pHS [Fig. 2A], as detected by quantitative RT-PCR in Fig. 2B [summarized in Fig. 2A]). RNase protection analysis confirmed that P4 RNA generated by all these mutants exhibited a wild-type ratio of R1 to R2 (13). Deletion of the SX and HS regions together (pSX+HS, Fig. 2A), however, resulted in substantial skipping of the NS2-specific exon (Fig. 2A and C). RNase protection assays showed that pSX+HS generated little R1 mRNA (13), demonstrating that the majority of the P4 product generated by the pSX+HS mutant skipped the NS2-specific exon. Deletions of approximately the same size as (pSma-Hinc) or somewhat larger than (pXho-Sac) pSX+HS (Fig. 2A), which contain the HS and SX elements alone, respectively, still allowed substantial exon inclusion (Fig. 2A and C). These data suggested a model in which the SX and HS regions function as two essential elements that have significantly redundant functions in governing the inclusion of the NS2-specific exon into mature mRNA. The difference in exon inclusion between pSma-Hinc (which retains the HS region) and pXho-Sac (which retains the SX region), however, suggested that at least in the context of these smaller mutant exons, the HS region plays a more critical role in exon inclusion, an observation which is further supported by point mutagenesis of the HS region described below.

View larger version (44K): [in this window] [in a new window]   FIG. 2.   A bipartite enhancer within the NS2-specific exon is required for inclusion of this exon in mature spliced mRNA. (A) The restriction sites within the NS2-specific exon (SmaI, XhoI, PstI, HincII, and SacI) which divide the exon into four regions (SX, XP, PH, and HS) and were used to generate the different exon deletion mutants are indicated (SX, for example, is a deletion between the SmaI and XhoI sites [see the text]). The SX1 to SX3 and HS1 to HS3 regions extend between the following nucleotide positions: SX1, nt 2002 to 2025; SX2, nt 2019 to 2052; SX3, nt 2050 to 2109; HS1, nt 2177 to 2196; HS2, nt 2196 to 2253; HS3, nt 2252 to 2270 (MVM nucleotide numbers as in reference 1). Quantitations of the direct percent R2/(R2+ES) ratio obtained by RT-PCR analysis for various mutants are also shown. All the values are the average of at least three separate experiments. Standard deviations are indicated in parentheses. ES values for pD1/2 are shown for comparison; the mutation is shown in Fig. 5A. (B) RT-PCR analysis of RNA generated by wild-type MVM (WT), mutants (described in the text), or mock transfected, as designated at the top of each lane. Samples were run on a 6% acrylamideurea gel. pD1/2 was used as a control for amplification of the ES. WT(RT) is a control reaction with wild-type RNA but excluding reverse transcriptase. An RNase protection analysis, with probe B, of RNA generated by the wild type was used as a marker (MARKER; the sizes of the marker bands are shown on the left) for the sizes of the RT-PCR-amplified bands. Wild-type RNA generated a 658-nt amplified R2 product, while RNA generated by the mutants showed R2 products of sizes consistent with the sizes of the deletions in these mutants. As explained in the legend to Fig. 5D, two kinds of amplified ES, using either A1 or A2, were observed. (C) RT-PCR analysis of RNA generated by wild-type MVM (WT), mutants (described in the text), or mock transfected, as designated at the top of each lane. Samples were run on a 6% acrylamide-urea gel. pD1/2 and WT(RT) controls, and the marker (MARKER; the sizes of the marker bands are shown on the right for the sizes of the RT-PCR-amplified bands) are as in panel B. Wild-type RNA generated a 658-nt amplified R2 product, while RNA generated by the mutants showed R2 products of sizes consistent with the sizes of the deletions in these mutants. As explained in the legend to Fig. 5D, two kinds of amplified ES using either A1 or A2 were observed.

View larger version (18K): [in this window] [in a new window]   View larger version (47K): [in this window] [in a new window]   FIG. 3.   Point mutations within the bipartite enhancer result in exon skipping. (A) The sequences of the wild-type and mutant SX1 and HS2 regions are shown underneath their appropriate map positions (with deviations from the wild-type sequence underlined), together with quantitations of the direct percent R2/(R2+ES) ratio obtained by RT-PCR analysis for each mutant. The CA-rich sequences in the SX1 region and the purine-rich sequences in the HS2 region are boxed and in boldface type. All the values are the average of at least three separate experiments. Standard deviations are indicated in parentheses. ES values for pD1/2 are shown for comparison; the mutation is shown in Fig. 5A. wt, wild type sequence. (B) RT-PCR analysis of RNA generated by wild-type MVM (WT), mutants (described in the text), or mock transfected, as designated at the top of each lane. Samples were run on a 6% acrylamide-urea gel. pD1/2 and WT(RT) controls and MARKER (the sizes of the marker bands are shown on the right) are as described in the legend to Fig. 2B. RNAs generated by either the wild type or the point mutants showed a 658-nt amplified R2 product. As explained in the legend to Fig. 5D, two kinds of amplified ES, using either A1 or A2, were observed.

A CA-rich element and a purine-rich element together constitute the bipartite enhancer of the NS2-specific exon. To determine which sequences within the SX1 and HS2 regions were the exon-defining motifs, we added both wild-type and mutant variants of the CA-rich element (CA1 and CA2, Fig. 4A) or the purine-rich element (AG1 and AG2; Fig. 4A) back to a mutant in which the SX1 and HS2 regions had been deleted (pSX1+HS2; Fig. 4A). Replacement of either the SX1 or HS2 regions of pSX1+HS2 with an oligonucleotide containing the two native CA-rich motifs separated by a 6-nt mutant spacer (CA2) [pSX1(CA2)+HS2, pSX1+HS2(CA2); Fig. 4A] restored exon inclusion to the parent construct (as shown by quantitative RT-PCR [Fig. 4]) to the same level as achieved by replacement with the authentic wild-type CA-rich element (CA1) [pSX1(CA1)+HS2 (Fig. 4); pSX1+HS2(CA1) (13)]. These results demonstrate that the CA-rich motifs within the SX1 region (and not the linker region) confer enhancer activity and that these sequences can function at either enhancer position, independent of the local sequence environment.

View larger version (25K): [in this window] [in a new window]   View larger version (67K): [in this window] [in a new window]   FIG. 4.   A CA-rich element and a purine-rich element together constitute the bipartite enhancer of the NS2-specific exon. (A) The sequences of the CA-rich and AG-rich oligonucleotides that were tested (deviations from the wild-type sequence are underlined; the sequences of the wild-type spacer in HS1 or the mutant spacers in AG1 and AG2 are described in Materials and Methods), and the positions at which they were replaced into pSX1+HS2 are indicated (see the text for details). The CA-rich sequences in the SX1 region and the purine-rich sequences in the HS2 region are boxed and in boldface type. Quantitations of the direct percent R2/(R2+ES) ratio obtained by RT-PCR analysis for each mutant are also shown. All the values are the average of at least three separate experiments. Standard deviations are indicated in parentheses. WT, wild-type sequence. , deletion. (B) RT-PCR analysis of RNA generated by wild-type MVM (WT), mutants (described in the text), or mock transfected, as designated at the top of each lane. Samples were run on a 6% acrylamideurea gel. pD1/2 and WT(RT) controls and MARKER (the sizes of the marker bands are shown on the left) are as described in the legend to Fig. 2B. RNA generated by WT showed a 658-nt amplified R2 product, while RNA generated by the mutants showed R2 products of sizes consistent with the sizes of the deletions and/or substitutions in these mutants. As explained in the legend to Fig. 5D, two kinds of amplified ES, using either A1 or A2, were observed.

The requirement of either the downstream 5' splice sites or the bipartite exonic enhancer for exon inclusion can be overcome by improvement of the upstream 3'-splice-site polypyrimidine tract. The native NS2-specific exon is flanked upstream by a poor 3' splice site (the exon 5' terminus) and downstream by an overlapping small intron with fairly consensus, although closely spaced, 5' splice sites (the exon 3' terminus). Deletion of the two downstream 5' splice sites, which leaves the NS2-specific exon without a strong terminus at either end, resulted in almost uniform skipping of this exon. This skipping could be suppressed by making even subtle improvements of the upstream 3'-splice-site polypyrimidine tract (pD1/2, p2TpptD1/2, p4TpptD1/2 [Fig. 5A]; shown by quantitative RT-PCR analysis and comparative RNase protection analysis in Fig. 5 and Table 1, as explained above) but not by changing the upstream 5' splice site to consensus (pCSDD1/2 [Fig. 5A]; shown by RT-PCR analysis in Fig. 5A and D]. When the downstream 5' splice sites were disabled, a cryptic donor within the NS2-specific exon was used (R2_cryptic; Fig. 5C). Improvement of the upstream 3'-splice-site polypyrimidine tract also substantially restored exon inclusion in RNA generated by a mutant lacking the bipartite exon enhancer (p4TSX+HS [Fig. 6A]; shown by RT-PCR analysis in Fig. 6A and C), and increased utilization of the cryptic donor (R2_cryptic; Fig. 5C and D), while improvement of the upstream 5' splice site in the same mutant (pCSDSX+HS; Fig. 6A) again had no effect (shown by RT-PCR analysis in Fig. 6A and C). RNase protection analyses with probe A (which detects all P4 products) revealed that the majority of the P4 product in p4TSX+HS were R2 mRNAs (13). Thus, the requirement for the bipartite exon enhancer, as well as for the downstream 5' splice site, could be overcome by improving the upstream 3'-splice-site polypyrimidine tract, perhaps by strengthening interactions at this weak polypyrimidine tract.

View larger version (46K): [in this window] [in a new window]   FIG. 5.   The NS2-specific exon of MVM requires only one strong exon terminus (upstream 3' splice site or downstream 5' splice site) to prevent exclusion from mature spliced mRNA. (A) The sequences of the large-intron 5'-splice-site and 3'-splice-site polypyrimidine tract and cleavage site in wild-type MVM and mutants are shown underneath their appropriate map positions (deviations from the wild-type sequence are underlined), with quantitations of the direct percent R2/(R2+ES) ratio obtained by quantitative RT-PCR (described fully in Materials and Methods). The presence or absence of the small-intron 5' splice sites in these constructs is indicated by either wt (presence) or  (absence). All the values are the average of at least three separate experiments. Standard deviations are indicated in parentheses. wt, wild type sequence. , deletion. (B) The two panels show RNase protection analyses with probe A (Fig. 1) of RNA generated by wild-type MVM (WT), mutants (as described in the text), or mock transfected, as designated at the top of each lane. The identities of the protected bands are shown on the left (in the left panel) and on the right (in the right panel). The larger species (R1) represents mRNA R1, while the major smaller species (R2+ES) represents RNA that uses the upstream large-intron 5' splice site at nt 514 (i.e., mRNA R2 plus the ES). The identities of the bands designated * and ** are unknown; however, they are probably breakdown products of the probe since they are not reproducibly seen and occasionally appear in lanes of mock-infected RNA (data not shown). (C) RNase protection analysis with probe B (Fig. 1), of RNA generated by wild-type MVM (WT), mutants (as described in the text), or mock transfected, as designated at the top of each lane. The identities of the protected bands for the wild type are shown on the left. The mutants were protected with versions of probe B homologous to the mutant region of the upstream intron 3'-splice-site polypyrimidine tract but nonhomologous in the region of D1 and D2, and therefore the RNA generated by these mutants shows fragments shorter than those generated by wild-type RNA. These mutants produce R1, R2, and R3 products that are unspliced across the small intron (designated R1un, R2un, and R3un, respectively) due to the loss of the two downstream small intron 5' splice sites, as well as R2 and R3 products that are spliced across the downstream small intron (designated R2cryptic and R3cryptic, respectively) by using a cryptic donor within the NS2-specific exon (see Discussion). Improvements of the upstream intron 3'-splice-site polypyrimidine tract disrupted the P38 promoter, resulting in decreased production of R3cryptic as well as R3un. *, undigested probe B. (D) RT-PCR analysis of RNA generated by wild-type MVM (WT), mutants (as described in the text), or mock transfected, as designated at the top of each lane, with primers a and b as shown in Fig. 1 and performed as explained in Materials and Methods. Samples were run on a 6% acrylamide-urea gel. WT(RT) is a control reaction with wild-type RNA but excluding reverse transcriptase. An RNase protection analysis with probe B of RNA generated by the wild type was used as a marker (MARKER; the sizes of the marker bands are shown on the right) for the sizes of the RT-PCR-amplified bands. WT RNA generated a 658-nt amplified R2 product. RNA generated by the mutants showed two kinds of amplified ES, both of which were considered in the quantitations: a larger (368-nt) product and a smaller (346-nt) product which represent exon skipping to 3' splice sites A1 and A2, respectively, of the downstream small intron. RNAs generated by pD1/2, p1TD1/2, p2TD1/2, and p4TD1/2 also show two kinds of amplified R2 products, which were considered in the quantitations; the largest of these is unspliced across the small intron, and the smaller two products (designated *) probably utilized a donor within the NS2-specific exon (see Discussion). RNAs generated by p5A and p1989 also showed the smaller R2 product that probably utilized a donor within the exon. The ES has previously been sequenced across the splice junction to confirm its identity (56).

View larger version (43K): [in this window] [in a new window]   FIG. 6.   Improvement of the upstream intron 3'-splice-site polypyrimidine tract can overcome exon skipping caused by deletion of the bipartite exon enhancer. (A) The restriction sites within the NS2-specific exon (SmaI, XhoI, PstI, HincII, and SacI) which were used to generate the exon deletion mutants and the sequences of the large-intron 5'-splice-site and 3'-splice-site polypyrimidine tract and cleavage site in the wild type and mutants are shown underneath their appropriate map positions (deviations from the wild-type sequence are underlined), together with quantitations of the direct percent R2/(R2+ES) ratio obtained by RT-PCR analysis for each mutant. All the values are the averages of at least three separate experiments. Standard deviations are indicated in parentheses. ES values for pD1/2 are shown for comparison; the mutation is shown in Fig. 5A. wt, wild-type sequence. , deletion. (B) RNase protection analyses with probe A (Fig. 1) of RNA generated by wild-type MVM (WT), mutants (as described in the text), or mock transfected, as designated at the top of each lane. The identities of the protected bands are shown on the left and explained in the legend to Fig. 5B. (C) RT-PCR analysis of RNA generated by wild-type MVM (WT), mutants (as described in the text), or mock transfected, as designated at the top of each lane. Samples were run on a 6% acrylamide-urea gel. pD1/2 and WT(RT) controls and MARKER (the sizes of the marker bands are shown on the left) are as described in the legend to Fig. 2B. RNA generated by the wild type showed a 658-nt amplified R2 product, while RNA generated by the mutants showed R2 products of sizes consistent with the sizes of the deletions in these mutants. As explained in the legend to Fig. 5D, two kinds of amplified ES, using either A1 or A2, were observed.

View larger version (10K): [in this window] [in a new window]   View larger version (41K): [in this window] [in a new window]   FIG. 7.   Inclusion of the NS2-specific exon tolerates doubling its length. (A) Quantitations of the direct percent R2/(R2+ES) ratio obtained by RT-PCR analysis for each mutant are shown. Construction of the mutants is explained in Materials and Methods. All the values are the average of at least three separate experiments. Standard deviations are indicated in parentheses. (B) RT-PCR analysis of RNA generated by wild-type MVM (WT), mutants (as described in the text), or mock transfected, as designated at the top of each lane. Samples were run on a 6% acrylamide-urea gel. MARKER is as described in the legend to Fig. 2B (the sizes of the marker bands are shown on the left). (Ex)-RT is a control reaction with p(Ex)-generated RNA but excluding reverse transcriptase. RNA generated by the wild type showed a 658-nt amplified R2 product, while RNA generated by the mutants showed R2 products of sizes consistent with the sizes of the substitutions in these mutants. As explained in the legend to Fig. 5D, two kinds of amplified ES, using either A1 or A2, were observed. The parent mutant bearing only the Sma sites at nt 2005 and 2270 [pEx()] is indistinguishable from the wild type with respect to splicing of the upstream intron and inclusion of the NS2-specific exon (56). Inclusion of the exon that is doubled in length still required wild-type exon sequences; when either one copy or two copies of the exon in the reverse orientation were inserted between the Sma sites [pEx() and pEx(), respectively (56)], the exon was almost uniformly skipped.

	DISCUSSION

Top Abstract Introduction Materials and methods Results Discussion References

Identification and characterization of a partially redundant bipartite enhancer within the NS2-specific exon. The NS2-specific exon bipartite enhancer was first identified by deletion and point mutagenesis (Fig. 2 and 3). This analysis indicated that the enhancer was composed of CA-rich and purine-rich elements within the 5' and 3' regions of the exon, respectively. Addition of both wild-type and mutant motifs to an exon mutant lacking the 5' and 3' enhancer regions resulted in reinclusion of the mutant exon (Fig. 4). These experiments demonstrated that the critical sequences within the upstream enhancer were two 5-nt CA-rich motifs separated by a 6-nt spacer and that the critical sequences within the downstream enhancer were two purine-rich motifs separated by a 22-nt spacer (Fig. 4A). These experiments also demonstrated that the CA-rich and purine-rich elements were able to function in a heterologous sequence context, i.e., at each other's positions within the exon, to efficiently include the NS2-specific exon. This confirmed that these two elements were bona fide ESEs which could function independently of the local sequence environment and also implied that these elements did not form critical secondary structures with the other exon sequences. Experiments to determine whether the CA-rich and purine-rich enhancer elements might stimulate the splicing of other heterologous 3' splice sites and to determine which cellular factors they interact with are in progress. The sequences of the NS2-specific exon enhancer elements are very highly conserved among the rodent parvoviruses, and these viruses have a wide host range (8). This suggests that these enhancer sequences may interact with prevalent cellular factors. It has been previously shown that tissue-specific alternative splicing of exon 4 of the calcitonin gene in thyroid C cells is also governed by both purine-rich and non-purine-rich exon enhancer elements (49).

Disabling the upstream 3' splice site of the NS2-specific exon does not result in exon skipping. It has been reported that mutations of the AG dinucleotide at 3' splice sites disrupt downstream exon inclusion, leading either to the utilization of a downstream AG or to skipping of the exon following the mutation, as predicted by the exon definition model (47, 48 reviewed in references 2 and 3). Surprisingly, when the already poor 3' splice site upstream of the NS2-specific exon was completely disabled, by mutation of either its cleavage site (p1989) or its polypyrimidine tract (p5A), almost all the steady-state P4-generated mRNAs were R1 molecules which included the NS2-specific exon but from which the large intron was not excised. Very little of either R2 or ES was generated (see Results and Table 2). Perhaps this is related to the presence of the exon-defining elements at each exon terminus and strong downstream 5' splice sites which together function to include the NS2-specific exon in such a way that it can be included at required levels in both R1 and R2.